Navigation Links
An 'important' reduction in risk of stent thrombosis with everolimus-eluting stent

Results of the independently-funded Bern-Rotterdam cohort study provide robust evidence of an "important" reduction in overall and very late stent thrombosis. The reduction in incidence was found when a newer generation everolimus-eluting stent (EES) was compared with early generation drug-eluting stents (DES) at long-term follow-up.

"The near elimination of stent thrombosis observed between one and four years after implantation shows that everolimus-eluting stents overcome the principal limitation of early generation DES," said investigator Dr Lorenz Rber from the University Hospital of Bern, Switzerland. "This an important advance in the safety of DES."

As background to the study, Dr Rber notes that the introduction of DES, which release anti-proliferative drugs from a polymer on the stent surface to prevent the formation of excessive scar tissue within the metallic scaffold (restenosis), was an important advance in the field of interventional cardiology, as revascularisation due to restenosis was significantly decreased. However, after the introduction of DES, data indicated that the formation of normal scar tissue was occasionally inhibited to such an extent that the stents were left uncovered. This was partly explained by inflammatory reactions against the polymer coating, presdisposing to stent thrombosis.

Although rare, stent thrombosis is a serious complication, which may result in death or acute myocardial infarction. Stent thrombosis occurring more than one year after implantation commonly referred to as very late stent thrombosis (VLST) has been observed more frequently in patients treated with early generation DES releasing the drugs paclitaxel or sirolimus than with bare metal stents and has emerged as a distinct entity complicating their use. The Bern-Rotterdam group has previously reported a steady annual risk of VLST of 0.6% up to five years following the implantation of early generation DES, a finding that has been confirmed by other trials and meta-analyses.

It is against this background that newer generation DES, such as everolimus-eluting stents, have been developed, to improve safety with the application of a more biocompatible polymer, along with a reduction in drug dose and reduced strut thickness. Whether these changes in design are sufficient to overcome VLST - the principal limitation of early generation DES - is to date not known.

The Bern-Rotterdam cohort study included more than 12,000 patients treated between 2002 and 2009 at the Bern University Hospital in Switzerland and the Thoraxcenter at Erasmus Medical Centre in Rotterdam, The Netherlands. The objective was to compare the incidence of stent thrombosis between newer generation DES eluting everolimus, and early generation DES eluting srolimus or paclitaxel, with particular focus on stent thrombosis occurring between one and four years (VLST).

Results showed that the rate of stent thrombosis up to four years was lower among patients treated with everolimus-eluting stents (1.4%) than with sirolimus-eluting stents (2.9%, p<0.0001) and paclitaxel-eluting stents (4.4%, p<0.0001). The reduction in stent thrombosis was most prominent between one and four years, resulting in a 67% risk reduction in VLST for the comparison of everolimus-eluting with sirolimus-eluting stents, and a 76 % risk reduction for the comparison of everolimus-eluting with paclitaxel-eluting stents.

Commenting on the results, Dr Rber said: "For the first time we now have robust evidence of the long-term therapeutic benefit of newer generation DES over the early generation DES. The virtual elimination of VLST in our findings provide reassurance of the long-term safety of these devices."


Contact: Jacqueline Partarrieu
European Society of Cardiology

Related medicine news :

1. Study finds important risk factors for death/transplantation in children with heart muscle disease
2. Dolphins remarkable recovery from injury offers important insights for human healing
3. Vascular disease management increasingly important
4. Family meals remain important through teen years, expert says
5. Concussion baseline important for accurate future assessment in at-risk youth athletes
6. Canadas Cancer Risk Management model is an important new health tool for policymakers
7. Freedom More Important to Happiness Than Wealth, Study Finds
8. Important monitoring of heart performance is omitted in two-thirds of high-risk surgical operations
9. Mothers Play Important Role in Recovery From Mental Illness
10. Important info about CHIPRA core set of recommended health care quality measures released
11. Ohio residents: Medical and health research important to states economy, jobs and incomes
Post Your Comments:
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
(Date:6/24/2016)... ... , ... Comfort Keepers® of San Diego, CA is excited to announce they ... to drive cancer patients to and from their cancer treatments. Comfort Keepers provides ... life and ongoing independence. Getting to and from medical treatments is one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
Breaking Medicine Technology: